Microalbuminuria as a predictive factor for cardiovascular events.

Area of Science:

• Cardiology
• Nephrology
• General Practice

Background:

• Microalbuminuria is an early marker of kidney damage and cardiovascular risk.
• Identifying high-risk patients in primary care is crucial for timely intervention.

Purpose of the Study:

• To evaluate microalbuminuria screening for identifying high-risk, non-diabetic hypertensive patients.
• To assess the impact of antihypertensive drug treatment on microalbuminuria levels.

Main Methods:

• A large cohort of untreated, non-diabetic hypertensive patients (n > 11,000) was screened for microalbuminuria using immunoassay test strips.
• Patients were analyzed for the prevalence of cardiovascular diseases (coronary artery disease, left ventricular hypertrophy, stroke, peripheral vascular disease).
• Regression analyses identified predictors of microalbuminuria and its association with cardiovascular complications. Patients received monotherapy with ACE inhibitors, beta-blockers, calcium antagonists, or diuretics.

Main Results:

• Microalbuminuria was present in 28-32% of patients and was significantly associated with higher rates of coronary artery disease, left ventricular hypertrophy, stroke, and peripheral vascular disease (p < 0.001).
• Systolic blood pressure, retinopathy, coronary artery disease, diastolic blood pressure, and left ventricular hypertrophy were independent predictors of microalbuminuria (p < 0.0001).
• All tested drug classes reduced microalbuminuria, with carvedilol demonstrating superior efficacy (p < 0.05).

Conclusions:

• Microalbuminuria screening effectively identifies high-risk hypertensive patients in general practice.
• Microalbuminuria is a significant, independent risk factor for cardiovascular complications in hypertensive individuals.
• Treatment targeting microalbuminuria, particularly with carvedilol, can mitigate cardiovascular risk.